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Abstract
Background: The occurrence of multimorbidity (i.e., the coexistence of multiple chronic diseases) increases with
age in older adults and is a growing concern worldwide. Multimorbidity has been reported to be a driving factor in
the increase of medical expenditures in OECD countries. However, to the best of our knowledge, there is no
published research that has examined the associations between multimorbidity and either long-term care
(LTC) expenditure or the sum of medical and LTC expenditures worldwide. We, therefore, aimed to examine
the associations of multimorbidity with the sum of medical and LTC expenditures for older adults in Japan.
Methods: Medical insurance claims data for adults ≥75 years were merged with LTC insurance claims data
from Kashiwa city, a suburb in the Tokyo metropolitan area, for the period between April 2012 and September 2013 to
obtain an estimate of medical and LTC expenditures. We also calculated the 2011 updated and reweighted version of
the Charlson Comorbidity Index (CCI) scores. Then, we performed multiple generalized linear regressions to examine
the associations of CCI scores (0, 1, 2, 3, 4, or≥ 5) with the sum of annual medical and LTC expenditures, adjusting for
age, sex, and household income level.
Results: The mean sum of annual medical and LTC expenditures was ¥1,086,000 (US$12,340; n = 30,042). Medical and
LTC expenditures accounted for 66 and 34% of the sum, respectively. Every increase in one unit of the CCI scores was
associated with a ¥257,000 (US$2920); 95% Confidence Interval: ¥242,000, 271,000 (US$2750, 3080) increase in the sum
of the expenditures (p < 0.001; n = 29,915).
Conclusions: Using a merged medical and LTC claims dataset, we found that greater CCI scores were associated with
a higher sum of annual medical and LTC expenditures for older adults. To the best of our knowledge, this is the first
study to examine the associations of multimorbidity with LTC expenditures or the sum of medical and LTC
expenditures worldwide. Our study indicated that the economic burden on society caused by multimorbidity
could be better evaluated by the sum of medical and LTC expenditures, rather than medical expenditures alone.
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Background
A steady increase in health-related spending has been a
great concern in the Organisation for Economic
Co-operation and Development (OECD) countries [1].
In Japan, the annual medical expenditures in 2016 were
approximately ¥42.1 trillion (approximately US$372 bil-
lion per the 2016 exchange rate) [2, 3], and the annual
long-term care (LTC) expenditures in 2016 were ap-
proximately ¥10.0 trillion (approximately US$88 billion)
[4]. These expenditures are projected to further increase
with a rapidly aging society, as is the case with many
OECD countries [1, 5]. Therefore, it is essential to iden-
tify the factors associated with the increase in these ex-
penditures to develop strategies to ensure sustainable
medical and LTC systems.
The occurrence of multimorbidity (i.e., the coexistence
of multiple chronic diseases) increases with age in older
adults. Multimorbidity is a growing concern worldwide, as
it has been reported to be associated with functional de-
cline, decreased quality of life, and possibly even higher
mortality [6]. Furthermore, multimorbidity has been re-
ported to be a driving factor in the increase of medical ex-
penditures in OECD countries [7, 8]. In Japan, however, to
the best of our knowledge, no population-based study has
been published that examined the associations of overall
multimorbidity with medical expenditures. While one
study included comorbidity as one of the covariates, its
population was limited to cancer patients at the end of life
[9]. There also have been a few studies that have focused
on the associations between specific medical conditions
(e.g., hypertension) and medical expenditures [10, 11] but
not the associations between overall multimorbidity and
medical expenditures.
Further, to the best of our knowledge, no published re-
search has examined the associations between overall
multimorbidity and either LTC expenditures or the sum
of medical and LTC expenditures worldwide. Mandatory
public LTC insurance systems have been introduced in
some OECD countries, such as Germany, the Netherland,
and South Korea [12, 13]. While there have been studies
published in these countries that examined the associa-
tions between various medical conditions and LTC expen-
ditures, these studies did not examine the associations of
overall multimorbidity with LTC expenditures. For in-
stance, a study from the Netherlands studied the selected
diseases separately rather than multimorbidity [14]. Simi-
larly, a study conducted in Germany examined the associ-
ations between dementia and both medical and long-term
care expenditures [15]. Also, a South Korean study exam-
ined the associations between dementia, stroke, both de-
mentia and stroke, and those who had neither dementia
nor stroke and LTC expenditures [16].
Japan developed its universal medical insurance system
in 1961 and implemented a new scheme in 2008. Every
individual who is at least 75 years old, except for those
receiving public assistance, is eligible for the Late-Stage
Medical Care System for the Elderly, which replaces the
medical insurance coverage for those who are less than
75 years old [17, 18]. Coverage by the Late-Stage Medical
Care System for the Elderly includes services provided
by medical professionals (e.g., doctors, nurses, various
therapists), diagnostic tests, prescriptions, surgery, and
anesthesia. In addition to the universal medical insur-
ance system, Japan also launched the mandatory public
LTC insurance system in 2000. Those aged 65 and older,
as well as those aged between 40 and 64 years with spe-
cific aging-related diseases, are eligible for the services,
including not only institutional care (e.g., long-term ad-
mission or short-term stay in a LTC facility) but also
community- and home-based care (e.g., adult day care,
outpatient rehabilitation, home help, or home-visit nurs-
ing) [12, 19].
The main purpose of our study was to examine the as-
sociations between baseline multimorbidity and annual
medical expenditures, LTC expenditures, and the sum of
both medical and LTC expenditures. We hypothesized
that greater multimorbidity was associated with both
higher medical and LTC expenditures, and hence the
sum of both types of expenditures. We also examined
the associations between multimorbidity and the level of
LTC required. In Japan, the level of LTC required con-
sists of seven levels (Support Levels 1–2, and Care
Levels 1–5), with Support Level 1 representing the low-
est level and Care Level 5 representing the highest level
of requirement for LTC. The level of LTC required is
assessed and approved systemically and reevaluated peri-
odically (at least every two years) [12]. For greater detail
on the evaluation process for LTC services in Japan,
please refer to Tamiya and colleagues’ article [11]. We
hypothesized that greater multimorbidity would be asso-
ciated with a higher level of LTC required.
Methods
Data source and participants
We obtained medical insurance claims data of the
Late-Stage Medical Care System for the Elderly (i.e.,
adults ≥75 years) and LTC insurance claims data from
the municipal government of Kashiwa City: a suburb in
the Tokyo metropolitan area. Kashiwa City had a popu-
lation of approximately 405,000 in 2012 with 8.7% of the
population being at least 75 years old in October 2012
[20]. Insurance claims data for the period between April
2012 and September 2013 were available for analysis at
the time of this study. In this study, we included those
who were enrolled in the Late-Stage Medical Care Sys-
tem for the Elderly (i.e., adults ≥75 years) between April
2012 and September 2013 in Kashiwa city (Fig. 1).
Mori et al. BMC Geriatrics           (2019) 19:69 Page 2 of 9
The datasets did not contain personally identifiable in-
formation; however, the same dummy ID numbers were
assigned to each individual in both medical and LTC
claim datasets. We merged the medical insurance claims
data for those aged ≥75 years with the LTC insurance
claims data at an individual level using these dummy ID
numbers. We could not obtain medical insurance claims
data for those covered by public assistance from the city;
therefore, we did not include these in this analysis.
We included medical insurance claims data from both
Diagnosis Procedure Combination/Per-Diem Payment
Systems (DPC/PDPS) and non-DPC/PDPS. DPC/PDPS
was introduced in Japan in 2003, and it offers a case-mix
payment system for acute inpatient care according to
diagnoses and procedures [20].
Measurements
From the medical insurance dataset, we obtained data re-
garding medical expenditures, including inpatient/out-
patient medical care payments and medication costs, but
did not include dental care, along with Charlson Comor-
bidity Index (CCI) scores, age (e.g., the 5-year ranges of
birth years [e.g., 1930–34]), and sex. From the LTC insur-
ance dataset, we obtained data on LTC expenditures, LTC
insurance premiums, and the level of LTC required.
To obtain the sum of medical and LTC expenditures
for the 12 months period, we totaled each month’s ex-
penditures, from and including the month, in which
medical insurance had been used for the first time since
April 2012 (i.e., the index month). The total amount of
expenditures included both insurance reimbursements
and co-payments for the covered services. The expendi-
tures were presented both as Japanese yen (¥) and U.S.
dollars ($; the mean exchange rate from April 2012 to
September 2013 was 88 Japanese yen to $1) [21], unless
otherwise specified.
We excluded those who did not use any medical insur-
ance during the period of analysis. We also excluded from
analysis those who had less than 12months of follow-up
data (Fig. 1) because we did not have comprehensive in-
formation regarding when they either obtained or lost
medical insurance. Additionally, we did not have informa-
tion regarding whether an individual lived in Kashiwa City
as of April 2012, or if he or she had moved from the city
during the study period. Finally, we did not have reliable
information regarding all deaths that occurred during the
period; the medical insurance dataset provided informa-
tion regarding death during hospitalization but did not in-
clude deaths that occurred outside of hospitals.
We calculated CCI scores, which were previously used as
a proxy for multimorbidity to predict future medical
Fig. 1 Flowchart of the study’s sample population
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expenditures [22, 23]. We used the 2011 updated and
reweighted version of the original CCI scores because these
updated scores have been validated in a Japanese national
administrative dataset to predict in-hospital mortality [24].
To define the multimorbidity in this study, we obtained
the CCI scores for the inclusive period within the three
months after the index month in which medical insurance
had been used for the first time since April 2012 (i.e., if
the index month was June 2012, the CCI scores were cal-
culated based on the claims data from June 2012 to Au-
gust 2012). We chose a period of three months because,
in Japan, neither medication prescriptions beyond a
three-month period nor refills are allowed, which gener-
ally requires patients to visit his or her physician at least
every three months for chronic conditions.
We identified conditions based on the International Clas-
sification of Diseases, Tenth Revision (ICD-10) codes that
were provided in the medical insurance dataset [25]. As the
ICD-10 codes in this dataset were only represented with in-
tegers (e.g., I11 for hypertensive heart disease instead of
I11.0 for hypertensive heart disease with congestive heart
failure), we also used the disease codes in the medical insur-
ance dataset, which provided more detailed information.
The conditions with a “suspicious” flag in the medical
claims dataset, which suggested that the diagnoses were
placed to justify diagnostic procedures, were not included
in the calculation of CCI scores. We treated the CCI vari-
able as a discrete variable and assigned scores that were
greater than 5 to the category of 5 (i.e., scores of 0, 1, 2, 3,
4, ≥ 5). This scoring rationale was based on one used in a
previous study [24] and on the distribution of CCI scores in
our study (i.e., the proportion of CCI scores ≥6 was only
3%; Table 1).
We followed the original definitions of all of the dis-
eases or medical conditions as much as possible [22].
However, in some instances, the diseases or medical
conditions we included did vary from the original defini-
tions. For details regarding these variations, please refer
to the information presented in Additional file 1.
The age variable was divided into two groups (i.e., the
5-year ranges for birth year < 1920–1924 or > 1925–
1930, which corresponded to age ≥ 87 years or age ≤ 86
years, respectively, as of January 1, 2012). As a proxy for
socioeconomic status, we used the LTC insurance pre-
miums category, which were based on household in-
come. The premiums category was divided into two
groups, a low-income group for those participants (along
with their family members) who were exempt from resi-
dents’ taxation and a middle-to-high income group for
the remaining participants [26].
Analysis
We first obtained the descriptive characteristics of the
sample, 12 months of medical expenditures, 12 months
of LTC expenditures, and the sum of these medical and
LTC expenditures. Next, we performed multiple general-
ized linear regressions with family gamma and long-link
function to examine the associations between the CCI
scores and 1) the sum of medical and LTC expenditures,
2) medical expenditures alone, and 3) LTC expenditures
alone, adjusting for age, sex, and household income level
Table 1 Descriptive characteristics of the study population
(N = 30,042a)
n (%)
Charlson Comorbidity Indexb
0 13,732 (45.7%)
1 3167 (10.5%)
2 7199 (24.0%)
3 2254 (7.5%)
4 1942 (6.5%)
5 787 (2.6%)
6 540 (1.8%)
7 216 (0.7%)
8 106 (0.4%)
9 52 (0.2%)
≥10 47 (0.2%)
Birth year (ages as of January 1, 2012)
1900–1914 (97–111) 162 (0.5%)
1915–1919 (92–96) 862 (2.9%)
1920–1924 (87–91) 2769 (9.2%)
1925–1929 (82–86) 6201 (20.6%)
1930–1934 (77–81) 11,137 (37.1%)
1935–1939 (72–76)c 8911 (29.7%)
Sex
Men 12,561 (41.8%)
Women 17,481 (58.2%)
Household income level (n = 29,915)
Low-income group 8823 (29.5%)
Middle-to-high income group 21,092 (70.5%)
Level of long-term care required
Not required 22,657 (75.4%)
Support level 1 586 (2.0%)
Support level 2 787 (2.6%)
Care level 1 1574 (5.2%)
Care level 2 1558 (5.2%)
Care level 3 1143 (3.8%)
Care level 4 918 (3.1%)
Care level 5 819 (2.7%)
aUnless otherwise specified
bThe 2011 updated and reweighted version
cWe included only those individuals who were enrolled in the Late-Stage
Medical Care System for the Elderly (i.e., adults ≥75 years) in this analysis
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[9]. In addition, to examine if the CCI scores were asso-
ciated with expenditures within the same level of LTC
required (i.e., LTC not required, Support Levels 1–2, and
Care Levels 1–5), we further stratified by each level of
LTC required and performed multiple generalized linear
regressions with family gamma and long-link function to
examine the associations between the CCI scores and
these expenditures, adjusting for the same covariates.
We then performed multiple ordinary logistic regres-
sions to examine the associations of the CCI scores with
the 7 levels of LTC required (reference: LTC not re-
quired), adjusting for age, sex, and household income
level. After performing these regressions, we used the
delta method to obtain the predicted coefficients of
medical, LTC, and the sum of both expenditures,
probabilities, and the 95% Confidence Intervals (CI).
All statistical tests were two-tailed with a significant
level of p < 0.05 using the STATA Version 14.2 (Stata-
Corp LP, College Station, TX, USA).
Results
Of 30,042 individuals, the descriptive statistics showed that
the mean and median scores of CCI were 1.42 and 1, re-
spectively (Table 1). For those who required LTC (n = 7385),
the mean and median scores were 2.01 and 2, respectively,
while for those who did not required LTC (n= 22,657), the
mean and median scores were 1.22 and 0, respectively. Men
and women accounted for 42 and 58%, respectively. Ages
were presented in five-year ranges based on birth year, and
88% fell into the ranges of 1925–1929, 1930–1934, and
1934–39, which corresponds to 88% of individuals being 86
years old or younger as of January 1, 2012 (Table 1). The
mean medical expenditures, LTC expenditures, and the sum
of these expenditures for 12months were ¥ 716,000 ($8140),
¥370,000 ($4200), and ¥1,086,000 ($12,340), respectively (n
= 30,042; Fig. 1, Table 2). Medical and LTC expenditures
accounted for 66 and 34%, respectively.
Multiple generalized linear regressions showed that
CCI scores were associated with higher amounts of each
expenditure, and therefore the sum of both types of ex-
penditures (p < 0.001, n = 29,915; Table 3; Fig. 1). For ex-
ample, every increase in one unit of CCI scores (0, 1, 2,
3, 4, or ≥ 5) was associated with a ¥257,000 ($2920) in-
crease in the sum of both medical and LTC expenditures
(95% CI [¥242,000, ¥271,000] or 95% CI [$2750, $3080]).
A simple generalized linear regression without adjusting
for these covariates (i.e., age, sex, and household income
level) showed ¥261,000 ($2970) increase in the sum of
the expenditures (95% CI [¥247,000, ¥275,000] or 95%
CI [$2810, $3130]; p < 0.001). After being stratified by
the level of LTC required, CCI scores were no longer as-
sociated with LTC expenditure in any of the level of LTC
required (p values ranging from 0.096 to 0.792, Table 3).
In the ordinal multiple logistic regression, greater CCI
scores were also associated with higher levels of LTC re-
quirements (p < 0.001; n = 29,915). For those with CCI
scores of 0, the predicted probabilities of not requiring
LTC or having Care Level 5 were 82.2% (95% CI [81.7,
82.7]) or1.6% (95% CI [1.5, 1.7]), respectively. On the
other hand, for those with CCI scores of 5 or higher, the
predicted probabilities of not requiring LTC or having
Care Level 5 were 54.7% (95% CI [53.3, 56.1]) or 6.6%
(95% CI [6.1, 7.1]), respectively (Fig. 2).
Discussion
In this population-based study using merged medical
and LTC claims data, greater CCI scores were associated
not only with higher medical expenditures, but also with
higher LTC expenditures, and hence with the sum of
both expenditures. Greater CCI scores were also associ-
ated with higher levels of LTC required. Our study,
therefore, suggested that the economic burden on soci-
ety caused by multimorbidity can be evaluated better by
considering both medical and LTC expenditures, rather
than medical expenditures alone.
To the best of our knowledge, this is the first study to
examine the associations between multimorbidity and
medical expenditures in Japan. Our study indicated that
greater multimorbidity was associated with higher med-
ical expenditures, which was consistent with the results
from other OECD countries [7, 8, 23]. In addition, in
our study, those who required LTC had higher mean
and median CCI scores compared with those who did
not require LTC.
More importantly, this is the first study, worldwide, to
examine the associations of multimorbidity with LTC ex-
penditures. In Japan, although there have been at least two
published studies that analyzed the determinants of LTC
expenditures [27, 28], and one study that included both
LTC and medical expenditures [29], these studies did not
include multimorbidity as either the main predictor vari-
able or as one of the covariates. Previous research appeared
to have used only LTC insurance claims data [27, 28] or
Table 2 Medical and long-term care expenditures for a 12-
month period (n = 30,042)
The sum of medical and long-term care ¥1,086,000
(US$ 12,340)
Medical ¥716,000
(US$ 8140)
Inpatient care ¥322,000
(US$ 3660)
Outpatient care ¥394,000
(US$ 4480)
Long-term care ¥370,000
(US$ 4200)
¥88 was equivalent to $1, which was the mean exchange rate from April 2012
to September 2013
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annual assessments and biennial surveys [29], which did
not contain the medical information necessary to identify
multimorbidity. In this research, we took a novel approach
in which we obtained medical and LTC claims data of the
entire city and merged them at an individual level. This
method enabled us to add LTC information to medical
claims data, add CCI scores to LTC claims data, and to cal-
culate the sum of medical and LTC expenditures.
We found that greater CCI scores were also associated
with higher levels of LTC requirements. Within the same
level of LTC, however, multimorbidity was not signifi-
cantly associated with LTC expenditures. Given that
higher levels of LTC have higher limits for benefits paid
for services per month [12], we concluded that greater co-
morbidity was associated with the higher levels of LTC,
leading to greater LTC expenditures. We further explored
and confirmed that higher levels of LTC were associated
with higher LTC expenditures in this study (p < 0.001, data
not shown). These results implied that unmet LTC needs
might exist, in which those who required higher levels of
LTC services could not receive sufficient services due to
the limits of the benefits paid for the services. Once their
LTC levels became higher, they could obtain more services
as the upper limits of the benefits increased. The existing
care situation (e.g., family environment) is not considered
when determining the LTC levels, potentially creating an
unmatched supply and demand for LTC services [30, 31].
An alternative explanation is that the supply might induce
the demand. In other words, care managers who play a
primary role in determining what services are provided by
the LTC system may use the upper limits of the benefits
regardless of the services an individual needed.
Our research has several limitations. First, it was chal-
lenging to obtain precise CCI scores based on the avail-
able claims data, as, for example, the original definition
of several conditions requires specific values that were
not available on the claims data. Additionally, tentative
diagnoses were sometimes given to justify diagnostic
procedures in a fee-for-service system. These diagnoses
were supposed to be tagged with a “suspicious” flag in
the medical claims data and were excluded from our
CCI score calculations. There also was a possibility that
tentative or false diagnoses were placed, so that medical
insurance would cover an individual’s prescriptions. Fur-
ther, there was a possibility that some diagnoses were
left out of the dataset because they were not related to
any procedure reimbursements or medication prescrip-
tions. We, however, made our best effort to obtain CCI
scores by using claims data to avoid these limitations.
Secondly, CCI scores did not fully assess the severity of
the participants’ chronic diseases, which may play an im-
portant role in the expenditures. Thirdly, the dataset did
not provide precise information as to when a participant
obtained or lost medical insurance eligibility; because of
this, we only included those with a minimum of 12
months of follow-up data. This approach was likely to
contribute to an underestimate of the expenditures, as it
has been reported that medical expenditures tend to in-
crease in the last months of life [32, 33]. Indeed, our
mean for medical expenditures was ¥ 716,000 ($8140),
Fig. 2 The predicted probabilities for long-term care use (n = 29,915). The level of long-term care required consists of seven levels (Support Levels
1–2, and Care Levels 1–5), with Support Level 1 representing the lowest level and Care Level 5 representing the highest level of requirement for
long-term care. Error bars represent the 95% Confidence Intervals. Results were obtained by ordinal logistic regressions, adjusting for age, sex, and
household income level.
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which was lower than the actual amount estimated by
the local government’s report (which was approximately
¥ 770, 000 ($8750) in 2013) [34]. In addition, there also
was a possibility that we might have excluded more se-
verely ill individuals (i.e., those with higher CCI scores),
who died within 12months from the index month, lead-
ing to underestimating the expenditures. Finally, we did
not include those who received public welfare due to the
unavailability of the data, which likely led to an under-
representation of the low-income group.
However, our study does have an important strength.
This is the first study to show that greater multimorbid-
ity was associated not only with medical expenditures
but also with LTC expenditures and hence with the sum
of both expenditures. Multimorbidity is a growing con-
cern in aging society and has been associated with mul-
tiple undesirable outcomes [6]. Our results suggested
that multimorbidity also imposed an economic burden
on society by increasing not only medical but also LTC
expenditures. Therefore, effective strategies to target for
reducing the prevalence of multimorbidity could provide
not only medical and functional but also economic ben-
efits for individuals and society. As the steady increase
in health-related spending has been a great concern in
OECD countries, our results are meaningful not only for
Japan but also for other countries.
Conclusions
In this population-based study using merged medical
and LTC claims data in Japan, we found that multimor-
bidity was positively associated with the sum of medical
and LTC expenditures in older adults. These results
demonstrated that it is important to sum both medical
and LTC expenditures to estimate the total economic
burden on society associated with multimorbidity.
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